JP2022539840A5 - - Google Patents

Info

Publication number
JP2022539840A5
JP2022539840A5 JP2022500764A JP2022500764A JP2022539840A5 JP 2022539840 A5 JP2022539840 A5 JP 2022539840A5 JP 2022500764 A JP2022500764 A JP 2022500764A JP 2022500764 A JP2022500764 A JP 2022500764A JP 2022539840 A5 JP2022539840 A5 JP 2022539840A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically
veterinarily acceptable
use according
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022500764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539840A (ja
JP7536243B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/069459 external-priority patent/WO2021005183A1/en
Publication of JP2022539840A publication Critical patent/JP2022539840A/ja
Publication of JP2022539840A5 publication Critical patent/JP2022539840A5/ja
Application granted granted Critical
Publication of JP7536243B2 publication Critical patent/JP7536243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022500764A 2019-07-10 2020-07-09 Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ Active JP7536243B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201930643 2019-07-10
ESP201930643 2019-07-10
PCT/EP2020/069459 WO2021005183A1 (en) 2019-07-10 2020-07-09 Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations

Publications (3)

Publication Number Publication Date
JP2022539840A JP2022539840A (ja) 2022-09-13
JP2022539840A5 true JP2022539840A5 (https=) 2023-07-18
JP7536243B2 JP7536243B2 (ja) 2024-08-20

Family

ID=71607975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500764A Active JP7536243B2 (ja) 2019-07-10 2020-07-09 Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ

Country Status (5)

Country Link
US (1) US20220257571A1 (https=)
EP (1) EP3996710B1 (https=)
JP (1) JP7536243B2 (https=)
ES (1) ES3014017T3 (https=)
WO (1) WO2021005183A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11958832B1 (en) 2023-10-12 2024-04-16 King Faisal University 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds
US11926611B1 (en) 2023-11-24 2024-03-12 King Faisal University 2-(2-ethoxyethoxy)-6-phenyl-4,4′-bipyridine-3-carbonitrile as an antimicrobial compound
US12071407B1 (en) 2023-12-05 2024-08-27 King Faisal University 6-(4-hydroxyphenyl)-2-(2-ethoxyethoxy)-4-(4-methoxyphenyl)nicotinonitrile as an antimicrobial compound
US11970451B1 (en) 2023-12-07 2024-04-30 King Faisal University 6-(3-hydroxyphenyl)-2-methoxy-4-(3-methylphenyl)nicotinonitrile as an antimicrobial compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2160780A1 (de) 1971-12-08 1973-06-14 Basf Ag Pyridino-pyrazole
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
JP2016527216A (ja) 2013-07-08 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリジン
EP3285809B1 (en) * 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections

Similar Documents

Publication Publication Date Title
JP2022539840A5 (https=)
ES2870805T3 (es) Tratamiento combinado de cáncer
CN113768933B (zh) Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途
US12281085B2 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
JP2019517510A (ja) 抗癌剤としてのホスホルアミデートヌクレオシド誘導体
CN102369010A (zh) 用于乳腺癌的利用奈拉替尼的治疗方案
EP3062790A1 (en) Pharmaceutical combinations for the treatment of cancer
CN111727059A (zh) 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法
JP2021523189A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物およびその使用方法
JP2024125139A5 (https=)
IL268416B1 (en) Pharmaceutical combinations for cancer treatment
US20150065526A1 (en) Overcoming acquired resistance to chemotherapy treatments through suppression of stat3
JP2024125140A5 (https=)
CN102688493B (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
JP2021511344A5 (https=)
CN101836989B (zh) 含有粉防己碱及粉防己碱类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
JP2023550740A5 (https=)
JP2014512362A5 (https=)
JP2024527974A5 (https=)
CN102688489A (zh) 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
JP2023531090A5 (https=)
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
CN102688490B (zh) 含有吴茱萸碱及吴茱萸碱类衍生物和Bc1-2抑制剂的药物组合物及其应用
TWI912688B (zh) 用於治療三陰性乳癌之藥物組合物
US20250099426A1 (en) Indolium Compounds for Treating Cancer